Since the FDA's breakthrough therapy designation came into existence as part of the FDA Safety and Innovation Act in July 2012, the agency has granted the designation to 145 drugs. Read More
Although Infinity Pharmaceuticals Inc. CEO Adelene Perkins said her firm's "going-in assumption is that we will be successful" in selling rights to phosphoinositide 3-kinase (PI3K) inhibitor duvelisib, Abbvie Inc.'s decision to pull out of their partnership undoubtedly threw cold water on the class. Read More
